

# Jorge Plutzky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5838968/publications.pdf>

Version: 2024-02-01

81  
papers

6,090  
citations

117625

34  
h-index

71685

76  
g-index

85  
all docs

85  
docs citations

85  
times ranked

8768  
citing authors

#	ARTICLE	IF	CITATIONS
1	Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program. American Heart Journal, 2022, 243, 15-27.	2.7	8
2	The Aging Aorta: Are We Only as Old as Our Endothelium?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 172-174.	2.4	1
3	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	2.3	23
4	Impact of coronary artery calcium testing on patient management. Journal of Cardiovascular Computed Tomography, 2022, 16, 303-308.	1.3	5
5	Perivascular Fibrosis Is Mediated by a KLF10-IL-9 Signaling Axis in CD4+ T Cells. Circulation Research, 2022, 130, 1662-1681.	4.5	6
6	Relationship Between Risk of Atherosclerotic Cardiovascular Disease, Inflammation, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis. Journal of the American Heart Association, 2022, 11, .	3.7	4
7	Shortwave infrared spatial frequency domain imaging for non-invasive measurement of tissue and blood optical properties. Journal of Biomedical Optics, 2022, 27, .	2.6	7
8	Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. European Journal of Preventive Cardiology, 2021, 28, e12-e14.	1.8	8
9	Digital Care Transformation. Circulation, 2021, 143, 507-509.	1.6	40
10	Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. American Heart Journal, 2021, 235, 104-112.	2.7	82
11	Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations. Current HIV/AIDS Reports, 2021, 18, 271-279.	3.1	24
12	Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction. JAMA Cardiology, 2021, 6, 880.	6.1	36
13	BRD2 regulation of sigma-2 receptor upon cholesterol deprivation. Life Science Alliance, 2021, 4, e201900540.	2.8	13
14	Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. American Journal of Preventive Cardiology, 2021, 8, 100278.	3.0	14
15	Retinoids Repress Human Cardiovascular Cell Calcification With Evidence for Distinct Selective Retinoid Modulator Effects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 656-669.	2.4	17
16	Intact vitamin A transport is critical for cold-mediated adipose tissue browning and thermogenesis. Molecular Metabolism, 2020, 42, 101088.	6.5	14
17	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. American Heart Journal, 2020, 229, 61-69.	2.7	137
18	Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2020, 5, 1430.	6.1	62

#	ARTICLE	IF	CITATIONS
19	Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry. <i>Diabetes Care</i> , 2020, 43, 1843-1850.	8.6	27
20	Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease. <i>JAMA Cardiology</i> , 2020, 5, 1182.	6.1	59
21	Epigenetic Therapeutics for Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1557.	7.4	3
22	BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs. <i>Circulation Research</i> , 2020, 126, 1190-1208.	4.5	88
23	To fast or not to fast: Lipid measurement and cardiovascular disease risk estimation in rural sub-Saharan Africa. <i>Journal of Global Health</i> , 2020, 10, 010407.	2.7	6
24	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM $\alpha$ ) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	6.8	104
25	The BD2 domain of BRD4 is a determinant in EndoMT and vein graft neointima formation. <i>Cellular Signalling</i> , 2019, 61, 20-29.	3.6	20
26	Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2439-2450.	2.8	69
27	Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration. <i>Current Diabetes Reports</i> , 2019, 19, 157.	4.2	7
28	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. <i>European Heart Journal</i> , 2019, 40, 2907-2919.	2.2	32
29	A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes. <i>Global Heart</i> , 2019, 14, 215.	2.3	24
30	Lipids in RA: Is Less Not Necessarily More?. <i>Current Rheumatology Reports</i> , 2018, 20, 8.	4.7	13
31	Predictors of a successful statin reattempt after an adverse reaction. <i>Journal of Clinical Lipidology</i> , 2018, 12, 643-651.	1.5	7
32	BET bromodomain proteins regulate enhancer function during adipogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2144-2149.	7.1	65
33	Cardiovascular Risk and Statin Eligibility of Young Adults After an MI. <i>Journal of the American College of Cardiology</i> , 2018, 71, 292-302.	2.8	145
34	Adiponectin concentration data improve the estimation of atherosclerotic risk in normal and in overweight subjects. <i>Clinical Endocrinology</i> , 2018, 88, 388-396.	2.4	4
35	Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease. <i>Circulation</i> , 2018, 137, 130-133.	1.6	7
36	Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2389-2398.	4.4	19

#	ARTICLE	IF	CITATIONS
37	Distribution and Performance of Cardiovascular Risk Scores in a Mixed Population of HIV-Infected and Community-Based HIV-Uninfected Individuals in Uganda. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 78, 458-464.	2.1	15
38	Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes. <i>Annals of Internal Medicine</i> , 2017, 167, 221.	3.9	80
39	Adipocyte arrestin domain-containing 3 protein (Arrdc3) regulates uncoupling protein 1 (Ucp1) expression in white adipose independently of canonical changes in $\beta^2$ -adrenergic receptor signaling. <i>PLoS ONE</i> , 2017, 12, e0173823.	2.5	8
40	Brown Fat and Browning for the Treatment of Obesity and Related Metabolic Disorders. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 12.	4.7	180
41	Epigenetic Changes in Diabetes and Cardiovascular Risk. <i>Circulation Research</i> , 2016, 118, 1706-1722.	4.5	98
42	Inhibition of BET bromodomain attenuates angiotensin II induced abdominal aortic aneurysm in ApoE <sup>-/-</sup> mice. <i>International Journal of Cardiology</i> , 2016, 223, 428-432.	1.7	15
43	Risk factors for lack of statin therapy in patients with diabetes and coronary artery disease. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1406-1413.	1.5	7
44	Extensive metabolic disorders are present in APC <sup>min</sup> tumorigenesis mice. <i>Molecular and Cellular Endocrinology</i> , 2016, 427, 57-64.	3.2	15
45	Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2016, 1859, 564-571.	1.9	45
46	Drivers of the Sex Disparity in Statin Therapy in Patients with Coronary Artery Disease: A Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0155228.	2.5	37
47	Association of monocyte tumor necrosis factor $\alpha$ expression and serum inflammatory biomarkers with walking impairment in peripheral artery disease. <i>Journal of Vascular Surgery</i> , 2015, 61, 155-161.	1.1	44
48	Emerging Epigenetic Maps in Atherosclerosis. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 573-575.	5.1	0
49	Diabetes and Cardiovascular Disease in Older Adults: Current Status and Future Directions. <i>Diabetes</i> , 2014, 63, 2578-2589.	0.6	185
50	Impact of pre-diabetes on heart transplant outcomes in patients with advanced heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 215-217.	0.6	3
51	Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 399-405.	2.3	75
52	NF- $\kappa$ B Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis. <i>Molecular Cell</i> , 2014, 56, 219-231.	9.7	507
53	Retinaldehyde dehydrogenase 1 deficiency inhibits PPAR $\gamma$ -mediated bone loss and marrow adiposity. <i>Bone</i> , 2014, 67, 281-291.	2.9	8
54	(Mis)interpreting studies on the adverse effects of statins. <i>BMJ, The</i> , 2014, 348, g3652-g3652.	6.0	2

#	ARTICLE	IF	CITATIONS
55	BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure. <i>Cell</i> , 2013, 154, 569-582.	28.9	346
56	Retinaldehyde Dehydrogenase 1 Coordinates Hepatic Gluconeogenesis and Lipid Metabolism. <i>Endocrinology</i> , 2012, 153, 3089-3099.	2.8	94
57	Retinaldehyde dehydrogenase 1 regulates a thermogenic program in white adipose tissue. <i>Nature Medicine</i> , 2012, 18, 918-925.	30.7	176
58	Macrovascular Effects and Safety Issues of Therapies for Type 2 Diabetes. <i>American Journal of Cardiology</i> , 2011, 108, 25B-32B.	1.6	35
59	The PPAR-RXR Transcriptional Complex in the Vasculature. <i>Circulation Research</i> , 2011, 108, 1002-1016.	4.5	138
60	Hyperlipidemia After Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2010, 116, 3457-3457.	1.4	0
61	Expansion and contraction: the mighty, mighty fatty acid. <i>Nature Medicine</i> , 2009, 15, 618-619.	30.7	10
62	Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR-RXR complex. <i>FEBS Letters</i> , 2008, 582, 32-38.	2.8	180
63	Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPAR. <i>Diabetes and Vascular Disease Research</i> , 2007, 4, S12-S14.	2.0	9
64	Peroxisome Proliferator-Activated Receptors and the Endothelium. , 2007, , 796-805.		0
65	Retinaldehyde represses adipogenesis and diet-induced obesity. <i>Nature Medicine</i> , 2007, 13, 695-702.	30.7	346
66	A Cardiologist's Perspective on Cardiometabolic Risk. <i>American Journal of Cardiology</i> , 2007, 100, S3-S6.	1.6	23
67	Inflammation in Atherosclerosis and Diabetes Mellitus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2004, 5, 255-259.	5.7	35
68	The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. <i>American Journal of Cardiology</i> , 2003, 92, 34-41.	1.6	70
69	MEDICINE: PPARs as Therapeutic Targets: Reverse Cardiology?. <i>Science</i> , 2003, 302, 406-407.	12.6	86
70	Diabetes as a vascular disease. Dyslipidemia as a target. <i>Postgraduate Medicine</i> , 2003, 113, 15-23.	2.0	0
71	Diabetic Macrovascular Disease. <i>Circulation</i> , 2002, 106, 2760-2763.	1.6	121
72	Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. <i>Journal of Diabetes and Its Complications</i> , 2002, 16, 401-415.	2.3	72

#	ARTICLE	IF	CITATIONS
73	PPAR $\alpha$ Activators Inhibit Tissue Factor Expression and Activity in Human Monocytes. Circulation, 2001, 103, 213-219.	1.6	177
74	Peroxisome Proliferator-Activated Receptors (PPARs) and Their Role in the Vessel Wall: Possible Mediators of Cardiovascular Risk?. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 203-210.	2.8	25
75	Statins for Stroke: The Second Story?. Circulation, 2001, 103, 348-350.	1.6	23
76	Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: Emerging insights for evolving paradigms. Current Atherosclerosis Reports, 2000, 2, 327-335.	4.8	77
77	PPAR $\gamma$ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 546-551.	2.4	355
78	PPAR $\alpha$ Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells. Circulation, 1999, 99, 3125-3131.	1.6	584
79	Effect of lipid-lowering therapy on vasomotion and endothelial function. Current Cardiology Reports, 1999, 1, 238-243.	2.9	14
80	Peroxisome Proliferator-Activated Receptor Gamma Activators Inhibit Gene Expression and Migration in Human Vascular Smooth Muscle Cells. Circulation Research, 1998, 83, 1097-1103.	4.5	565
81	PPARs in Atherosclerosis. , 0, , 401-417.		0